1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Themis Medicare Limited

Themis Medicare Limited

94.59
INR
-1.30
(-1.36%)
4.32EPS
25.29P/E
10.09BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
23.08
23.84
27.3
23.75
22.72
19.89
21.82
24.96
42.54
37.43
40.92
43.47
36.9
35.93
Basic EPS, GAAP
0.32
0.73
1.91
1.77
1.23
-1.17
2.7
3.89
7.92
6.18
4.73
3.24
0.12
4.33
Free Cash Flow per Basic Share
0.09
1.51
2.09
-0.77
-0.19
0.58
-0.6
4.24
1.5
-1.38
0.4
2.1
-0.88
- -
Dividend per Share
0.09
0.18
0.18
- -
- -
- -
- -
0.17
0.43
0.5
0.5
0.5
0.5
- -
Book Value per Share
6.69
6.99
12.81
16.86
18.4
17.22
19.92
23.78
31.25
36.88
41.03
43.74
43.28
- -
Tangible Book Value per Share
6.67
6.97
12.54
16.63
18.19
17.04
19.76
23.65
31.14
36.8
40.97
43.71
43.26
- -
Basic Weighted Avg Shares
85
85
85
90
92
92
92
92
92
92
92
92
92
92
Sales/Revenue/Turnover
1,951
2,019
2,324
2,147
2,086
1,826
2,004
2,293
3,913
3,445
3,766
4,001
3,398
3,316
Operating Margin (%)
7.54
8.22
15.2
11.99
8.54
-3.12
13.7
17.85
22.01
16.54
10.42
9.79
-2.92
-15.76
Depreciation Expense
94
115
119
75
74
80
83
85
95
105
122
99
103
103
Net Income, GAAP
27
62
163
160
113
-107
248
357
729
569
435
298
11
400
Effective Tax Rate (%)
32.23
- -
11.16
9.13
0.9
- -
7.79
13.62
23.49
21.53
18.56
24.81
40.69
26.77
Profit Margin (%)
1.38
3.08
7
7.43
5.41
-5.88
12.36
15.57
18.62
16.52
11.56
7.46
0.34
12.05
Working Capital
-27
-21
-297
2
181
32
257
572
1,046
1,254
1,402
1,477
1,388
- -
LT Debt
768
746
283
124
115
94
121
234
243
284
268
186
219
- -
Total Equity
565
592
1,091
1,524
1,688
1,581
1,830
2,185
2,875
3,394
3,777
4,026
3,986
- -
Return on Invested Capital (%)
5.24
- -
16.15
11.14
7.54
- -
9.67
12
19.48
11.03
6.94
6.05
-1.29
- -
Return on Capital (%)
6.34
- -
13.31
12.2
9.29
- -
13.39
15.35
23.15
15.81
10.99
7.55
1.3
- -
Return on Common Equity (%)
4.96
10.73
19.35
12.21
7.03
-6.57
14.53
17.78
28.81
18.15
12.14
7.65
0.29
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
782
- -
LT Borrowings
- -
210
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
9,265
6,085
10,090

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,050
- -
Cash, Cash Equivalents & STI
- -
156
- -
Accounts Receivable, Net
- -
1,781
- -
Inventories
- -
811
- -
Total Current Liabilities
- -
1,662
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
782
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.58%
13.3%
-1%
Free Cash Flow
-173.36%
-20.63%
-142.19%
Net Income, GAAP
-58.19%
-13.79%
-96.17%
Sales/Revenue/Turnover
6.04%
11.84%
-15.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,230
1,170
938
717
4,001
2026
976
780
901
765
3,398
2027
870
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.68
1.55
0.06
-1.05
3.24
2026
-1.54
-0.39
1.1
0.96
0.12
2027
2.67
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.5
2026
- -
- -
- -
- -
0.5
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sachin Dinesh Patel
Full Time Employees
1,696
Sector
Health technology
Industry
Pharmaceuticals: major
Address
11/12 Udyog Nagar Industrial Estate Mumbai MA India 400104
IPO Date
Apr 2, 2007
Website
themismedicare.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Themis Medicare Limited operates as a pharmaceutical enterprise, engaging in the development and global distribution of medicinal products. The company focuses on manufacturing both active pharmaceutical ingredients and a diverse range of finished formulations, addressing critical needs across several therapeutic segments including anti-infective, antimalarial, anti-tuberculosis, cardiology, general health and nutrition, oncology, ophthalmology, and pain management. Known for its innovative approach, Themis Medicare utilizes patented platform technologies to create differentiated parenteral formulations and advanced drug delivery systems, such as the patented ETOJET, a pioneering Etoricoxib injectable, and EMAL, an indigenous once-daily antimalarial. The firm was established in 1969, initially as Themis Chemicals, before adopting its current name in 2001, and maintains its primary operational base in Mumbai, India. While expanding its presence to over 44 countries, Themis Medicare has also recently reported a consolidated net loss of ₹3.62 crores for the second quarter of fiscal year 2026, alongside a 33.35% year-on-year decline in net sales to ₹77.99 crores. The company continues to advance its robust research and development pipeline, with 31 new drug delivery system projects in progress, and aims to strengthen its position in the hospital business sector.